Advanced Endometrial Cancer Pipeline Gains Momentum as ADCs, Immunotherapy and Targeted Combinations Reshape Treatment
核心洞察
The advanced endometrial cancer (搜索) pipeline is expanding rapidly, with immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) driving a more competitive and biomarker-driven market.
Merck (搜索)'s Phase III TroFuse-005 trial met its primary endpoints of overall survival and progression-free survival for the investigational TROP2 (搜索)-directed ADC sacituzumab tirumotecan in advanced or recurrent endometrial cancer.
Genmab's rinatabart sesutecan (Rina-S) achieved a 50.0% confirmed objective response rate, including two complete responses, in heavily pretreated advanced endometrial cancer (搜索) patients.
Advanced endometrial cancer (搜索) — disease that has spread beyond the uterus or recurred after initial treatment — is entering a period of rapid therapeutic transformation, with antibody-drug conjugates (ADCs), immunotherapy combinations, and biomarker-driven targeted agents reshaping a historically challenging treatment landscape. According to Stuti Mahajan, consulting manager at DelveInsight, "advanced endometrial cancer is a challenging, often recurrent or metastatic form of disease where treatment innovation is reshaping the therapeutic landscape," with the market "gaining momentum as immunotherapies, targeted agents, and ADCs emerge, broadening treatment options while driving a more competitive and increasingly biomarker-driven market."
ADC Advances Dominate Recent Clinical Milestones
Several antibody-drug conjugates have delivered notable clinical results in advanced endometrial cancer (搜索). In May 2026, Merck (搜索) announced that the pivotal Phase III TroFuse-005 trial evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2 (搜索)-directed ADC developed in collaboration with Kelun-Biotech (搜索), met its primary endpoints of overall survival (OS) and progression-free survival (PFS) in certain patients with advanced or recurrent endometrial cancer.
In April 2026, BioNTech SE reported positive results from the primary analysis of a Phase II cohort evaluating trastuzumab pamirtecan (BNT323/DB-1303) in patients with HER2 (搜索)-expressing advanced endometrial cancer (搜索) whose disease progressed on or after first-line chemotherapy, with or without prior checkpoint inhibitor treatment.
Genmab A/S also presented updated data in October 2025 from cohort B2 of the Phase I/II RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®). At a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) produced a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (搜索) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. In August 2025, the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to Rina-S for the treatment of adult patients with recurrent or progressive endometrial cancer who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.
Targeted Combinations and Regulatory Momentum
The PI3K/AKT/mTOR (搜索) pathway has emerged as a key target in biomarker-selected disease. In August 2026, Faeth Therapeutics (搜索) announced that the FDA granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and who have previously been treated with platinum-based chemotherapy and an immune checkpoint inhibitor (ICI).
This asset changed hands in February 2026, when Sensei Biotherapeutics, Inc. announced its acquisition of Faeth Therapeutics (搜索) Inc. The acquisition brought PIKTOR — a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR (搜索) pathway through PI3K-alpha and dual mTORC1/2 targeting — into Sensei's pipeline.
Immunotherapy Combinations Reshape Frontline Treatment
Immunotherapy-chemotherapy combinations are reshaping frontline treatment for advanced endometrial cancer (搜索). Three checkpoint inhibitor combinations received regulatory clearance between January 2024 and March 2025 after demonstrating improved outcomes compared with platinum-based chemotherapy alone. Dostarlimab combined with carboplatin and paclitaxel extended median overall survival to 44.6 months, compared with 28.2 months for chemotherapy. Pembrolizumab-based regimens improved progression-free survival by 70% in mismatch repair-deficient tumors, while durvalumab reduced the risk of disease progression by 58% in the DUO-E trial.
These clinical results have accelerated updates to national treatment guidelines and increased demand for biomarker testing and companion diagnostics. Regulatory approvals in Canada and the European Union demonstrate growing international alignment, helping successful multinational clinical trials translate more rapidly into commercial opportunities.
Market Growth and Access Challenges
The global endometrial cancer market is projected to expand from USD 30.60 billion in 2025 to USD 32.09 billion in 2026, and is forecast to reach USD 40.66 billion by 2031, registering a compound annual growth rate (CAGR) of 4.86% from 2026 to 2031. Growth is supported by rising disease prevalence, an ageing female population, increasing obesity rates, advances in molecular diagnostics, and the rapid adoption of immunotherapy-chemotherapy combinations.
North America held a leading 37.25% market share in 2025, while Asia-Pacific is forecast to record the fastest regional CAGR of 8.93% through 2031. Endometrial carcinoma accounted for 73.10% of market revenue in 2025, while uterine sarcomas are forecast to grow at a 7.84% CAGR.
High treatment costs remain a significant constraint. Checkpoint inhibitor combinations carry premium prices, with incremental cost-effectiveness ratios exceeding USD 150,000 per quality-adjusted life year for mismatch repair-proficient tumors. Research indicates that dostarlimab plus chemotherapy would require a 15% price reduction to meet established willingness-to-pay thresholds in China. Recurrent endometrial cancer also creates a substantial financial burden, adding approximately USD 84,562 in annual costs per patient compared with non-recurrent disease.
A Broadening Pipeline
The advanced endometrial cancer (搜索) pipeline spans multiple mechanisms of action, including PD-L1, VEGFR inhibitors, XPO1 inhibition, DNA topoisomerase I inhibitors, programmed cell death 1 receptor antagonists, autologous tumor-infiltrating lymphocyte (TIL) replacement, NF-E2-related factor 2 stimulants, and NF-kappa B inhibitors. Key companies include Pfizer, Genmab, Incyte Corporation, MacroGenics, Huabo Biopharm Co., Ltd., BioMimetix JV, LLC, Iovance Biotherapeutics, Inc., Karyopharm Therapeutics Inc., Evergreen Therapeutics, Inc., BioNTech SE, Outpace Bio, and Tarapeutics Science Inc. Notable pipeline therapies include PF-08634404, rinatabart sesutecan, retifanlimab, HB0025, BMX-001 plus paclitaxel, lifileucel, selinexor, EG-007, BNT329, OPB-201, and TR115.